Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018538 · ClinicalTrials.gov registry record · Phase 2
Calcifidol Therapy in Men With Cancer
A Phase 2 study of Prostate Cancer, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00018538: Completed Phase 2 study of Prostate Cancer, sponsored by US Department of Veterans Affairs.
NCT00018538 is a Phase 2 study of Prostate Cancer that has completed, run by US Department of Veterans Affairs. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00018538, a Phase 2 study of Prostate Cancer, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
Prostate cancer is a common occurrence in the aging population, with one in ten men destined to develop the disease. 40% of patients with prostate cancer experience a recurrence after definitive treatment. This study addresses the as-yet unresolved problem of the optimal management of early recurrence as manifested by increase in the accepted marker for this disease, PSA. Vitamin D, an agent with cell-differentiating properties, has been shown to inhibit angiogenesis and cause differentiation of prostate cancer cells in the laboratory and to affect PSA favorably in clinical studies of patients with advanced prostate cancer. This study will assess the effects of vitamin D in patients with sub-clinical biochemical relapses of prostate cancer as indicated by rising PSA but low tumor burdens, with the potential for developing an approach to this problem that will delay or prevent progression.
Conditions Studied
Interventions
- DRUG calcifidiol
Study Locations (1)
Florida
- VAMC Miami, FL - Miami
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2002-09 |
| Phase | Phase 2 |
What the finished NCT00018538 record still lists
NCT00018538 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which calcifidiol is the first listed.
NCT00018538 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00018538 about?
NCT00018538 is a clinical study titled "Calcifidol Therapy in Men With Cancer". Prostate cancer is a common occurrence in the aging population, with one in ten men destined to develop the disease. 40% of patients with prostate cancer experience a recurrence after definitive treatment. This study addresses the as-yet unresolved problem of the optimal management of early recurren...
What is the current status of trial NCT00018538?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-10. Estimated completion is 2002-09.
What conditions does trial NCT00018538 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00018538?
The interventions under investigation include: calcifidiol (DRUG).
Who is sponsoring clinical trial NCT00018538?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00018538 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia